Highest Recommended Dose of Vraylar (Cariprazine)
The maximum recommended daily dose of Vraylar is 6 mg for adults with schizophrenia or bipolar mania, 4.5 mg for adolescents (ages 10-17) with these conditions, and 3 mg for adults with bipolar depression or as adjunctive treatment for major depressive disorder. 111
Dosing by Indication
Schizophrenia
Adults: Maximum 6 mg/day orally once daily 11
- Start at 1.5 mg/day, can increase to 3 mg on Day 2
- Further adjustments in 1.5 mg or 3 mg increments based on response
- Important caveat: Doses above 6 mg daily do not provide increased effectiveness sufficient to outweigh dose-related adverse reactions 1
Adolescents (13-17 years): Maximum 4.5 mg/day orally once daily 1
- Start at 0.5 mg/day, increase to 1.5 mg on Day 3
- Can titrate to 3 mg on Day 5 and 4.5 mg on Day 8
Bipolar Mania (Acute Manic or Mixed Episodes)
Adults: Maximum 6 mg/day orally once daily 2221
- Start at 1.5 mg/day, increase to 3 mg on Day 2
- Recommended range is 3-6 mg/day
- Doses above 6 mg daily show no additional benefit 1
Adolescents (10-17 years): Maximum 4.5 mg/day orally once daily 1
- Start at 0.5 mg/day, increase to 1.5 mg on Day 3, then 3 mg on Day 5
- Can increase to 4.5 mg on Day 8 if needed
Bipolar Depression
- Adults only: Maximum 3 mg/day orally once daily 2221
- Start at 1.5 mg/day
- Can increase to 3 mg on Day 15 based on response
- This is notably lower than the mania dose
Major Depressive Disorder (Adjunctive Treatment)
- Adults only: Maximum 3 mg/day orally once daily 11
- Start at 1.5 mg/day
- Can increase to 3 mg on Day 15
- Critical point: Dosage titration at intervals less than 14 days resulted in higher incidence of adverse reactions 1
Key Clinical Considerations
Why Different Maximum Doses?
The lower maximum dose for bipolar depression and MDD (3 mg vs 6 mg) reflects the risk-benefit profile. Research shows that 1.5 mg daily was the optimal dose for adjunctive treatment in MDD, with the 3 mg dose being less consistently effective 3. For bipolar depression, the 1.5-3 mg range provides efficacy with better tolerability 22.
Pharmacokinetic Warning
Changes in dose will not be fully reflected in plasma for several weeks due to cariprazine's long half-life (1-3 weeks for the active metabolite didesmethyl-cariprazine) 14. Prescribers must monitor patients for adverse reactions and treatment response for several weeks after starting or changing doses.
Dose Modifications with CYP3A4 Inhibitors
When taking strong CYP3A4 inhibitors, maximum doses are substantially reduced 1:
- For patients on 4.5-6 mg: reduce to 0.75 mg/day
- For patients on 1.5-3 mg: reduce to 0.5 mg/day
Common Pitfalls
Akathisia is dose-dependent: Higher doses (4.5-6 mg) show 12.5% incidence vs 9% at 1.5-3 mg 4. The lower dose range (1-2 mg) has better akathisia tolerability (NNH=24) compared to higher doses (NNH=9) 5
Extrapyramidal symptoms increase with dose: 15% at 1.5-3 mg vs 19% at 4.5-6 mg 4
Don't rush titration in depression: The 14-day interval before increasing from 1.5 mg to 3 mg in MDD is evidence-based to reduce adverse events 1
Avoid exceeding 6 mg in schizophrenia/mania: Clinical trials demonstrate no additional efficacy benefit but increased side effects 11